News by ACCESS Newswire on TradingView, 2026-08-18 — tag:reuters.com,2026-08-18:newsml_ACSTLNwBa:0
• NanoViricides has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 Oral Gummies. • The trial is being conducted under the leadership of Professor Katoto, with Patrick, a Fogarty Fellow and member of the Institute for Health Metrics, involved in the process. • This development is significant as it advances the testing of NV-387, moving the drug candidate closer to potential commercialization and clinical use.
tradingview.com